NCT00408473 is a Phase 4 clinical trial of Flecainide in Atrial Fibrillation, sponsored by MEDA Pharma GmbH & Co. KG.

Who is sponsoring NCT00408473?

NCT00408473 is sponsored by MEDA Pharma GmbH & Co. KG.

What drugs are being tested in NCT00408473?

Interventions in NCT00408473: Flecainide.

What condition does NCT00408473 study?

NCT00408473 studies Atrial Fibrillation.

Is NCT00408473 still recruiting?

NCT00408473 is currently terminated. Last updated 7 February 2022.

Last reviewed 2022-02-07 · How we verify

NCT00408473

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.

Terminated Phase 4 Last updated 7 February 2022

What this trial tests

Phase 4 trial testing Flecainide in Atrial Fibrillation in 256 participants. Terminated before completion.

Quick facts

Lead sponsor	MEDA Pharma GmbH & Co. KG
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	256
Sites	47 locations across France, Netherlands, Belgium, Germany, Romania, Bulgaria, Spain

Drugs / interventions tested

Flecainide (FLECAINIDE) — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

MEDA Pharma GmbH & Co. KG — full company profile →

Who can join

Adults 18 to 65, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the efficacy of flecainide controlled release (CR) in the prevention of recurrent AF during 9 months of active treatment compared to placebo in patients with only one documented AF episode.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tic-Tac: A Translational Approach in Mechanisms Associated with Irregular Heartbeat and Sinus Rhythm Restoration in Atrial Fibrillation Patients.
Parra-Lucares A, Villa E, Romero-Hernández E, Méndez-Valdés G, et al · · 2023 · PMID 37629037 · DOI 10.3390/ijms241612859

Verify or expand the search:

Other trials of Flecainide

Trials testing the same drug.

NCT06142604 — Single Dose Flecainide for Early Sinus Rhythm Conversion of Perioperative Atrial Fibrillation After Noncardiac Surgery · Phase 4 · withdrawn
NCT04837261 — Shortening Duration of Antiarrhythmic Medication for SVT in Infants · completed
NCT02347111 — Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation · Phase 4 · recruiting
NCT03587558 — Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract · Phase 4 · unknown

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other MEDA Pharma GmbH & Co. KG trials

Trials by the same sponsor.

NCT06126952 — Azelastine Allergen Chamber - Onset of Action Study · Phase 2 · completed
NCT05544695 — Real-world Evidence Study on Cystistat · completed
NCT04652245 — Dymista Allergen Chamber - Onset of Action Study · Phase 4 · completed
NCT03599791 — DYmista NAsal Spray in CHInese Patients · Phase 3 · completed
NCT03004131 — MP-AzeFlu Allergen Chamber - Onset of Action Study · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00408473 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MEDA Pharma GmbH & Co. KG
Last refreshed: 7 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00408473.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing